Related Experiment Video
Updated: May 28, 2026
14:45
Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein
Published on: July 29, 2022
Α-synuclein misfolding and Parkinson's disease
Leonid Breydo1, Jessica W Wu, Vladimir N Uversky
1Department of Molecular Medicine, College of Medicine, University of South Florida, Tampa, FL 33612, USA.
Biochimica Et Biophysica Acta
|October 26, 2011
Summary
Parkinson's disease (PD) is linked to alpha-synuclein aggregation. This review explores alpha-synuclein
Area of Science:
- Neuroscience
- Molecular Biology
- Biochemistry
Background:
- Alpha-synuclein (α-synuclein) is a presynaptic protein implicated in Parkinson's disease (PD).
- It is the primary component of Lewy bodies and Lewy neurites, pathological hallmarks of PD.
- Alpha-synuclein is an intrinsically disordered protein, adopting various conformations.
Purpose of the Study:
- To review the different aggregation states of α-synuclein.
- To examine the molecular mechanisms underlying α-synuclein aggregation.
- To investigate factors influencing α-synuclein conformation and aggregation in PD.
Main Methods:
- Literature review of existing research on α-synuclein.
- Analysis of conformational states, aggregation pathways, and influencing factors.
- Synthesis of evidence linking α-synuclein aggregation to PD pathogenesis.
Main Results:
- Identified distinct α-synuclein conformational states: membrane-bound, partially-folded, oligomeric, and aggregated forms.
- Highlighted the partially-folded state as a critical intermediate in aggregation and fibrillation.
- Emphasized the role of aggregation and conformational changes in the molecular basis of PD.
Conclusions:
- The aggregation and conformational dynamics of α-synuclein are central to Parkinson's disease.
- Understanding these processes is crucial for elucidating PD's molecular mechanisms.
- Environmental and genetic factors significantly modulate α-synuclein aggregation.
Related Concept Videos
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
01:37Neural Regulation
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.